Repression of transforming growth factor-β receptor type I promoter expression by Sp1 deficiency

Sumudra Periyasamy, Sudhakar Ammanamanchi, Manoranjani P.M. Tillekeratne, Michael G. Brattain

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

In this report, we describe the mechanism of TGF-β receptor type I (RI) repression in the GEO human colon carcinoma cells. Treatment of GEO cells with the DNA methyltransferase inhibitor, 5 azacytidine induced RI expression and restored TGF-β response. A stably transfected RI promoter-reporter construct (RI-Luc) expressed higher activity in the 5 aza C treated GEO cells, suggesting the activation of a transactivator for RI transcription. Gel shift analysis indicated enhanced binding of proteins from the 5 aza C treated nuclear extracts to radiolabeled Sp1 oligonucleotides specifically contained in the RI promoter. Protein stability studies after cyclohexamide treatment suggested an increase in the Sp1 protein stability from the 5 aza C treated GEO cells. Further, transfection of Sp1 cDNA into untreated GEO control cells increased RI promoter activity and thus induced RI expression. 5 aza C mediated Sp1 expression in Sp1 deficient GEO colon and MCF-7 breast cancer cells also enhanced the activity of several other Sp1 dependent promoters such as TGF-β receptor type II (RII), Cyclin A and p21/waf1/cip1. These results indicate that restoration of Sp1 in several different types of Sp1 deficient cells leads to enhanced activation of a wide range of Sp1 dependent promoters.

Original languageEnglish (US)
Pages (from-to)4660-4667
Number of pages8
JournalOncogene
Volume19
Issue number40
DOIs
StatePublished - Sep 21 2000

Fingerprint

Growth Factor Receptors
Transforming Growth Factors
Protein Stability
Colon
Azacitidine
Cyclin A
Trans-Activators
Methyltransferases
Electrophoretic Mobility Shift Assay
Oligonucleotides
Transfection
Carrier Proteins
Complementary DNA
Breast Neoplasms
Carcinoma
DNA

Keywords

  • Azacytidine
  • Transforming growth factor-β
  • Transforming growth factor-β receptor type I (RI)

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Periyasamy, S., Ammanamanchi, S., Tillekeratne, M. P. M., & Brattain, M. G. (2000). Repression of transforming growth factor-β receptor type I promoter expression by Sp1 deficiency. Oncogene, 19(40), 4660-4667. https://doi.org/10.1038/sj.onc.1203822

Repression of transforming growth factor-β receptor type I promoter expression by Sp1 deficiency. / Periyasamy, Sumudra; Ammanamanchi, Sudhakar; Tillekeratne, Manoranjani P.M.; Brattain, Michael G.

In: Oncogene, Vol. 19, No. 40, 21.09.2000, p. 4660-4667.

Research output: Contribution to journalArticle

Periyasamy, S, Ammanamanchi, S, Tillekeratne, MPM & Brattain, MG 2000, 'Repression of transforming growth factor-β receptor type I promoter expression by Sp1 deficiency', Oncogene, vol. 19, no. 40, pp. 4660-4667. https://doi.org/10.1038/sj.onc.1203822
Periyasamy, Sumudra ; Ammanamanchi, Sudhakar ; Tillekeratne, Manoranjani P.M. ; Brattain, Michael G. / Repression of transforming growth factor-β receptor type I promoter expression by Sp1 deficiency. In: Oncogene. 2000 ; Vol. 19, No. 40. pp. 4660-4667.
@article{0eea1cbff9cf4c28a40f9002820d5809,
title = "Repression of transforming growth factor-β receptor type I promoter expression by Sp1 deficiency",
abstract = "In this report, we describe the mechanism of TGF-β receptor type I (RI) repression in the GEO human colon carcinoma cells. Treatment of GEO cells with the DNA methyltransferase inhibitor, 5 azacytidine induced RI expression and restored TGF-β response. A stably transfected RI promoter-reporter construct (RI-Luc) expressed higher activity in the 5 aza C treated GEO cells, suggesting the activation of a transactivator for RI transcription. Gel shift analysis indicated enhanced binding of proteins from the 5 aza C treated nuclear extracts to radiolabeled Sp1 oligonucleotides specifically contained in the RI promoter. Protein stability studies after cyclohexamide treatment suggested an increase in the Sp1 protein stability from the 5 aza C treated GEO cells. Further, transfection of Sp1 cDNA into untreated GEO control cells increased RI promoter activity and thus induced RI expression. 5 aza C mediated Sp1 expression in Sp1 deficient GEO colon and MCF-7 breast cancer cells also enhanced the activity of several other Sp1 dependent promoters such as TGF-β receptor type II (RII), Cyclin A and p21/waf1/cip1. These results indicate that restoration of Sp1 in several different types of Sp1 deficient cells leads to enhanced activation of a wide range of Sp1 dependent promoters.",
keywords = "Azacytidine, Transforming growth factor-β, Transforming growth factor-β receptor type I (RI)",
author = "Sumudra Periyasamy and Sudhakar Ammanamanchi and Tillekeratne, {Manoranjani P.M.} and Brattain, {Michael G.}",
year = "2000",
month = "9",
day = "21",
doi = "10.1038/sj.onc.1203822",
language = "English (US)",
volume = "19",
pages = "4660--4667",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "40",

}

TY - JOUR

T1 - Repression of transforming growth factor-β receptor type I promoter expression by Sp1 deficiency

AU - Periyasamy, Sumudra

AU - Ammanamanchi, Sudhakar

AU - Tillekeratne, Manoranjani P.M.

AU - Brattain, Michael G.

PY - 2000/9/21

Y1 - 2000/9/21

N2 - In this report, we describe the mechanism of TGF-β receptor type I (RI) repression in the GEO human colon carcinoma cells. Treatment of GEO cells with the DNA methyltransferase inhibitor, 5 azacytidine induced RI expression and restored TGF-β response. A stably transfected RI promoter-reporter construct (RI-Luc) expressed higher activity in the 5 aza C treated GEO cells, suggesting the activation of a transactivator for RI transcription. Gel shift analysis indicated enhanced binding of proteins from the 5 aza C treated nuclear extracts to radiolabeled Sp1 oligonucleotides specifically contained in the RI promoter. Protein stability studies after cyclohexamide treatment suggested an increase in the Sp1 protein stability from the 5 aza C treated GEO cells. Further, transfection of Sp1 cDNA into untreated GEO control cells increased RI promoter activity and thus induced RI expression. 5 aza C mediated Sp1 expression in Sp1 deficient GEO colon and MCF-7 breast cancer cells also enhanced the activity of several other Sp1 dependent promoters such as TGF-β receptor type II (RII), Cyclin A and p21/waf1/cip1. These results indicate that restoration of Sp1 in several different types of Sp1 deficient cells leads to enhanced activation of a wide range of Sp1 dependent promoters.

AB - In this report, we describe the mechanism of TGF-β receptor type I (RI) repression in the GEO human colon carcinoma cells. Treatment of GEO cells with the DNA methyltransferase inhibitor, 5 azacytidine induced RI expression and restored TGF-β response. A stably transfected RI promoter-reporter construct (RI-Luc) expressed higher activity in the 5 aza C treated GEO cells, suggesting the activation of a transactivator for RI transcription. Gel shift analysis indicated enhanced binding of proteins from the 5 aza C treated nuclear extracts to radiolabeled Sp1 oligonucleotides specifically contained in the RI promoter. Protein stability studies after cyclohexamide treatment suggested an increase in the Sp1 protein stability from the 5 aza C treated GEO cells. Further, transfection of Sp1 cDNA into untreated GEO control cells increased RI promoter activity and thus induced RI expression. 5 aza C mediated Sp1 expression in Sp1 deficient GEO colon and MCF-7 breast cancer cells also enhanced the activity of several other Sp1 dependent promoters such as TGF-β receptor type II (RII), Cyclin A and p21/waf1/cip1. These results indicate that restoration of Sp1 in several different types of Sp1 deficient cells leads to enhanced activation of a wide range of Sp1 dependent promoters.

KW - Azacytidine

KW - Transforming growth factor-β

KW - Transforming growth factor-β receptor type I (RI)

UR - http://www.scopus.com/inward/record.url?scp=0034699344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034699344&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1203822

DO - 10.1038/sj.onc.1203822

M3 - Article

C2 - 11030155

AN - SCOPUS:0034699344

VL - 19

SP - 4660

EP - 4667

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 40

ER -